Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1491144-00-3
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of avacincaptad pegol during breastfeeding. Since only a small dose in injected intravitreally into the eye, it is unlikely that a clinically relevant amount would reach the infant in breastmilk.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Avacincaptad Pegol
CAS Registry Number
1491144-00-3
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- Avacincaptad pegol (Izervay) for geographic atrophy in age-related macular degeneration.[Med Lett Drugs Ther. 2024]Avacincaptad pegol (Izervay) for geographic atrophy in age-related macular degeneration.. Med Lett Drugs Ther. 2024 Jan 22; 66(1694):15-16.
- Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.[Lancet. 2023]Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, et al. Lancet. 2023 Oct 21; 402(10411):1449-1458. Epub 2023 Sep 8.
- C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.[Ophthalmology. 2021]C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.Jaffe GJ, Westby K, Csaky KG, Monés J, Pearlman JA, Patel SS, Joondeph BC, Randolph J, Masonson H, Rezaei KA. Ophthalmology. 2021 Apr; 128(4):576-586. Epub 2020 Sep 1.
- Review Avacincaptad Pegol: First Approval.[Drugs. 2023]Review Avacincaptad Pegol: First Approval.Kang C. Drugs. 2023 Oct; 83(15):1447-1453.
- Review Pegcetacoplan.[Drugs and Lactation Database (...]Review Pegcetacoplan.. Drugs and Lactation Database (LactMed®). 2006
- Avacincaptad Pegol - Drugs and Lactation Database (LactMed®)Avacincaptad Pegol - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...